Kura Oncology (NASDAQ:KURA) SVP Thomas James Doyle Sells 4,607 Shares of Stock

Kura Oncology, Inc. (NASDAQ:KURA) SVP Thomas Doyle sold 4,607 shares of the stock in a transaction on Monday, September 28th. The shares were sold at an average price of $10.50, for a total transaction of $48,373.50. Following the completion of the sale, the senior vice president directly owned 142,428 shares in the company, valued at approximately $1,495,494. This represents a 3.13% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Kura Oncology Trading Up 1.9%

Kura Oncology stock traded up $0.20 during mid-day trading on Tuesday, hitting $10.81. The company’s stock had a trading volume of 1,890,260 shares, compared to its average volume of 1,673,937. The company has a debt-to-equity ratio of 0.12, a quick ratio of 4.71 and a current ratio of 4.73. The company has a 50 day moving average of $11.22 and a 200-day moving average of $10.15. Kura Oncology, Inc. has a one year low of $7.36 and a one year high of $13.90. The stock has a market cap of $961.66 million, a PE ratio of -3.21 and a beta of 0.44.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.77) EPS for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.11. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. The firm had revenue of $20.87 million for the quarter, compared to analysts’ expectations of $20.16 million. On average, research analysts anticipate that Kura Oncology, Inc. will post -3.25 EPS for the current year.

More Kura Oncology News

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: KO-7246 regenerated functional pancreatic beta-cell mass and improved glycemic control in Type 1 and Type 2 diabetes models. Benefits persisted for at least one month after treatment stopped in a Type 1 diabetes model, suggesting potential disease-modifying activity. KO-7246 EASD announcement
• Positive Sentiment: The candidate increased beta-cell mass, endogenous insulin and C-peptide levels, and showed enhanced activity when combined with semaglutide. Results in human pancreatic islets also indicated selective beta-cell proliferation and improved glucose-responsive insulin secretion, strengthening the potential commercial value of Kura’s menin-inhibitor platform. KO-7246 preclinical data
• Neutral Sentiment: KO-7246 remains preclinical. Caspian plans IND-enabling work and a future Phase 1 study, with management scheduled to discuss the program on October 13. Any valuation benefit for KURA therefore depends on future clinical progress and the terms of Kura’s relationship with Caspian. Caspian and Kura KO-7246 report
• Negative Sentiment: Several Kura executives and insiders sold shares on September 28–29, including Mollie Leoni, Brian Powl, Kathleen Ford, Thomas Doyle and Teresa Bair. The transactions totaled approximately 97,000 shares and more than $1 million, signaling near-term insider selling pressure even though the sellers retained substantial holdings. Kura insider ownership filing
• Negative Sentiment: The diabetes opportunity carries substantial execution risk, including potential clinical or regulatory setbacks, unexpected safety findings and the need for additional financing before human trials can begin.

Institutional Investors Weigh In On Kura Oncology

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Tidal Investments LLC purchased a new position in Kura Oncology in the second quarter worth $1,029,000. WINTON GROUP Ltd lifted its holdings in shares of Kura Oncology by 26.2% during the 2nd quarter. WINTON GROUP Ltd now owns 13,000 shares of the company’s stock valued at $143,000 after purchasing an additional 2,700 shares during the last quarter. Integrated Wealth Concepts LLC acquired a new stake in shares of Kura Oncology in the 2nd quarter worth $159,000. IFP Advisors Inc grew its stake in Kura Oncology by 136.5% during the 2nd quarter. IFP Advisors Inc now owns 2,542 shares of the company’s stock worth $28,000 after buying an additional 1,467 shares during the last quarter. Finally, Allworth Financial LP increased its position in Kura Oncology by 148.4% during the 2nd quarter. Allworth Financial LP now owns 10,326 shares of the company’s stock valued at $113,000 after buying an additional 6,169 shares in the last quarter.

Analysts Set New Price Targets

KURA has been the subject of a number of research reports. Sanford C. Bernstein set a $24.00 price objective on shares of Kura Oncology in a research note on Monday, June 15th. Morgan Stanley set a $24.00 price target on shares of Kura Oncology in a report on Monday, August 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kura Oncology in a research note on Friday, July 17th. Citizens Jmp reissued a “market outperform” rating and set a $24.00 price objective on shares of Kura Oncology in a report on Monday, August 24th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a research note on Thursday, June 4th. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $25.40.

About Kura Oncology

Kura Oncology, Inc is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company’s research programs target specific genetic and molecular abnormalities that contribute to tumor growth, with an emphasis on hematologic malignancies and selected solid tumors.

Kura’s leading program has been ziftomenib, an oral, selective menin inhibitor being developed for genetically defined forms of acute myeloid leukemia, including cancers with NPM1 mutations or certain KMT2A rearrangements.